

Ofev - (100, 150 mg; Capsule, Oral)

Generic Name	Nintedanib	Innovator	Boehringer Ingelheim
Dosage	100, 150 mg; Capsule, Oral	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	More Than 5
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Ofev is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.